Ovid Therapeutics Inc (OVID)

02:05 AM

Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies - TipRanks

02:05 AM

Mar 11, 2025

Ovid Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com UK

Mar 11, 2025

Mar 11, 2025

Ovid Therapeutics stock plunges to 52-week low of $0.46 - Investing.com India

Mar 11, 2025

Mar 11, 2025

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025

Mar 11, 2025

Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025

Mar 11, 2025

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 11, 2025

Mar 11, 2025

Ovid Therapeutics Secures 2-Year Cash Runway as 3 Novel Drug Programs Progress - StockTitan

Mar 11, 2025

Mar 11, 2025

We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate - Yahoo Finance

Mar 11, 2025

Mar 07, 2025

Ovid Therapeutics (OVID) Expected to Announce Earnings on Friday - Defense World

Mar 07, 2025

Mar 06, 2025

Trump's FDA chief pick Makary to face overhauling agency, keeping Kennedy happy -March 06, 2025 at 06:00 am EST - Marketscreener.com

Mar 06, 2025

Mar 06, 2025

Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.03 Consensus Target Price from Brokerages - Defense World

Mar 06, 2025

Mar 05, 2025

Ovid Therapeutics appoints new board member and updates compensation policy - Investing.com India

Mar 05, 2025

Mar 05, 2025

Ovid Therapeutics appoints new board member and updates compensation policy By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 05, 2025

Ovid Therapeutics Expands Board with New Appointment - TipRanks

Mar 05, 2025

Mar 04, 2025

Ovid Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView

Mar 04, 2025

Mar 03, 2025

Ovid Therapeutics Appoints Dr. Stelios Papadopoulos To Board - citybiz

Mar 03, 2025

Mar 03, 2025

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors - GlobeNewswire

Mar 03, 2025

Mar 01, 2025

Ovid therapeutics CBFO sells $2,185 in stock - Investing.com India

Mar 01, 2025

Mar 01, 2025

Ovid therapeutics CBFO sells $2,185 in stock By Investing.com - Investing.com Australia

Mar 01, 2025

Feb 28, 2025

Ovid therapeutics president and COO sells $2,956 in stock By Investing.com - Investing.com Canada

Feb 28, 2025

Feb 28, 2025

Ovid therapeutics president and COO sells $2,956 in stock - Investing.com India

Feb 28, 2025

Feb 27, 2025

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

Want Insights on Brain Condition Treatments? Ovid Therapeutics Set for Major Healthcare Conference - StockTitan

Feb 27, 2025

Feb 25, 2025

Ovid Therapeutics stock hits 52-week low at $0.55 - Investing.com India

Feb 25, 2025

Feb 25, 2025

Ovid Therapeutics stock hits 52-week low at $0.55 By Investing.com - Investing.com UK

Feb 25, 2025

Feb 20, 2025

Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight - GlobeNewswire Inc.

Feb 20, 2025

Feb 19, 2025

Analyzing Madrigal Pharmaceuticals (NASDAQ:MDGL) & Ovid Therapeutics (NASDAQ:OVID) - Defense World

Feb 19, 2025

Feb 18, 2025

Dup15q Syndrome Market Expected to rise, 2032 | Ovid - openPR

Feb 18, 2025

Feb 15, 2025

SG Americas Securities LLC Purchases 17,172 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World

Feb 15, 2025

Feb 14, 2025

Ovid Therapeutics faces Nasdaq delisting over share price - MSN

Feb 14, 2025

Feb 13, 2025

Ovid Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa

Feb 13, 2025

Feb 13, 2025

Ovid Therapeutics IncReceives Nasdaq Notice For Minimum Bid Price Non-Compliance - Marketscreener.com

Feb 13, 2025

Feb 12, 2025

Ovid stock plunges to 52-week low, touches $0.59 amid downturn - MSN

Feb 12, 2025

Feb 11, 2025

Ovid therapeutics president and COO acquires $4,971 in stock - MSN

Feb 11, 2025

Feb 10, 2025

Dup15q Syndrome Drugs Market Size Report 2032 | Ovid - openPR

Feb 10, 2025

Feb 06, 2025

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Feb 06, 2025

Feb 05, 2025

Epilepsy Market Expected to rise, 2034 | Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven - Barchart

Feb 05, 2025

Feb 05, 2025

Healthcare Spotlight: Ovid Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan

Feb 05, 2025

Feb 03, 2025

Ovid Therapeutics (NASDAQ:OVID) Upgraded by Oppenheimer to Outperform Rating - MarketBeat

Feb 03, 2025

Feb 01, 2025

Oppenheimer raises Ovid stock rating, sets $4 price target - MSN

Feb 01, 2025

Feb 01, 2025

Ovid Therapeutics stock hits 52-week low at $0.68 amid downturn - MSN

Feb 01, 2025

Jan 31, 2025

Ovid upgraded to outperform by Oppenheimer, OV329 cited - MSN

Jan 31, 2025

Jan 30, 2025

Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’ - Yahoo Finance

Jan 30, 2025